Euthyrox (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

Euthyrox (Levothyroxine Sodium) by Provell Pharmac: Off-Patent Genericized (AB Competition), 7 AB generics, $613K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorProvell Pharmac
FDA Application & PathwayN021292 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$613K
2024 Medicare Part D Spend$485K
2024 Medicaid Spend$129K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel